Isis snags $7M from GSK pact for antiviral drug work; Evolva licenses out diabetic drug to Serodus;

@FierceBiotech: Still trending: What happens to the  in a government shutdown? Story | Follow @FierceBiotech

@JohnCFierce: Pharma companies paid $25K to attend academics' summit on FDA trial rules. Pay to play. Report | Follow @JohnCFierce

@DamianFierce: Analyst: Bet on another boom for big CROs. More from FierceCRO | Follow @DamianFierce

@EmilyMFierce: Chemical in red wine kills cancer cells even after it's metabolized. Story from FierceBiotech Research | Follow @EmilyMFierce

> Carlsbad, CA-based Isis Pharmaceuticals' ($ISIS) has earned $7 million in milestone payments from GlaxoSmithKline ($GSK) for the advancement of its antiviral drug candidate ISIS-GSK3Rx under the companies' collaboration. More

> Swiss Evolva is licensing EV-077, its compound for diabetic nephropathy, to Norwegian biotech Serodus ASA, which will initiate the next clinical study on EV-077 in 2014. Release

> Eddingpharm and Immutep have struck an agreement, giving Eddingpharm exclusive rights to develop and market Immutep's ImmuFact IMP321 in China, Hong Kong, Macau, and Taiwan for breast cancer and other first-line metastatic indications. News

Medical Device News

@FierceMedDev: Edwards' stock starts rebounding after FDA expanded approval for Sapien valve. ICYMI Friday | Follow @FierceMedDev

@MarkHFierce: Atossa is issuing a voluntary recall of its breast cancer test to address FDA regulatory concerns. News | Release | Follow @MarkHFierce

@MichaelGFierce: Check out FierceBiotech's new mobile app! Here's some more info | Follow @MichaelGFierce

> FDA: Medtronic, CardioMEMS panel reviews are on despite government shutdown. Story

> Delcath axes one-third of staff after FDA rejection. More

> Boreal Genomics raises $18M to support Dx test and genomic tool expansion. Item

Pharma News

@FiercePharma: Sanofi chief's latest growth promise: Q4 will bring it. Story | Follow @FiercePharma

@EricPFierce: FDA approved another new hot flash drug, this one from Pfizer, Ligand. ICYMI last week | Follow @EricPFierce

@CarlyHFierce: ICYMI: Activist investor fumes over Otsuka bid for Astex. More | Follow @CarlyHFierce

> J&J's Doxil shortage to last until at least end of 2014. Article

> Merck, AstraZeneca, Pfizer top list of biggest pharma job-cutters. More

> Forget drug-sales forecasts, study finds: They're mostly wrong. Report

CRO News

> Analyst: Bet on another boom for big CROs. Report

> Covance launches lab management service to cut study costs. Article

> Biocon: Syngene is Asia's fastest-growing CRO. Item

> Boehringer pulls plug on CMO biz, plots 1,100 job cuts. Story

> CRO TranScrip reaches into Hong Kong. News

> AMRI snags drug development deal with U.K. government. More

Biotech IT News

> IBM updates open-source Big Data disease modeling platform. Report

> Low-profile cloud service provider steps into limelight. Item

> Ambitious U.K. genome project looks for industry input. News

> Bioinformatics projects stall as shutdown stops NIH funding. Story

> Bill advances case for nationwide track-and-trace databases. More

> Experts tip bioinformatics collaborations to improve breast cancer care. Article

And Finally... A chemical found in red wine was able to kill cancer cells even after it was metabolized by the body, U.K. scientists have found. Story

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.